# Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

> **NCT05221619** · — · TEMPORARILY_NOT_AVAILABLE · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Warm Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** Nipocalimab

## Key facts

- **NCT ID:** NCT05221619
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** TEMPORARILY_NOT_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05221619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05221619, "Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05221619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*